Insulin-like growth factor I is a dual effector of multiple myeloma cell growth

Blood

Volumn 96, Issue 8, 2000, Pages 2856-2861

  Ge, N L ^a   Rudikoff, S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN RECEPTOR SUBSTRATE 1; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CONTROLLED STUDY; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SCID MOUSE; SIGNAL TRANSDUCTION;

EID: 0034667606     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v96.8.2856.h8002856_2856_2861     Document Type: Article

References (38)

1. Plasma cell myeloma: New biological insights and advances in therapy
2. Biology and treatment of multiple myeloma
3. The treatment of multiple myeloma
4. Interleukin 6 is essential for in vivo development of B lineage neoplasms
5. Defective development of pristane-oil-induced plasmacytomas in interleukin-6-deficient BALB/c mice
6. Distinct tumorigenic potential of abl and raf in B cell neoplasia: abl Activates the IL-6 signaling pathway
7. Interleukin-6 in human multiple myeloma
8. Role of interleukin 6 in the growth of myeloma-derived cell lines
9. Major role of the soluble interleukin-6/interleukin-6 receptor complex for the proliferation of interleukin-6-dependent human myeloma cell lines
10. Interleukin 3 and interleukin 6 synergistically promote the proliferation and differentiation of malignant plasma cell precursors in multiple myeloma
11. Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: Correlation with disease activity and other prognostic parameters
12. Interleukin-6 in multiple myeloma: Correlation with disease activity and Ki-67 proliferation index
13. Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma
14. Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma
15. Translocated c-myc oncogene of Burkitt lymphoma is transcribed in plasma cells and repressed in lymphoblastoid cells
16. p16/INK4a and p15/INK4b gene methylation and absence of p16/INK4a mRNA and protein expression in Burkitt's lymphoma
17. Growth of human malignant lymphoid cell lines in serum-free medium
18. Adult T leukemia cells produce a lymphokine that augmerits interleukin 2 receptor expression
19. IRS-1 is a common element in insulin and insulin-like growth factor-I signaling to the phosphatidylinositol 3'-kinase
20. Role of IRS-2 in insulin and cytokine signalling
21. The IRS-signaling system: A network of docking proteins that mediate insulin and cytokine action
22. Insulin receptor substrate-1 mediates phosphatidylinositol 3'-kinase and p70S6k signaling during insulin, insulin-like growth factor-1, and interleukin-4 stimulation
23. The protein kinase encoded by the Akt proto-oncogene is a target of the PDG F-activated phosphatidylinositol 3-kinase
24. Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction
25. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B
26. Akt signaling: Linking membrane events to life and death decisions
27. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery
28. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt
29. Insulin and IGF-1 increase mitogenesis and glucose metabolism in the multiple myeloma cell line, RPMI 8226
30. Insulin-like growth factor I is a growth and survival factor in human multiple myeloma cell lines
31. A role for insulin-like growth factor in the regulation of IL-6-responsive human myeloma cell line growth
32. The role of the insulin-like growth factor system in human cancer
33. Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death
34. Tumor necrosis factor induces phosphorylation and translocation of BAD through a phosphatidylinositide-3-OH kinase-dependent pathway
35. Multiple myeloma cells are protected against dexamethasone-induced apoptosis by insulin-like growth factors
36. IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade
37. Blockade of mitogen-activiated protein kinase cascade signaling in interleukin 6-independent multiple myeloma cells
38. Functional insulin and insulin-like growth factor-1 receptors are preferentially expressed in multiple myeloma cell lines as compared to B-lymphoblastoid cell lines